Literature DB >> 32220770

Prognostic factors for heart recovery in adult patients with acute fulminant myocarditis and cardiogenic shock supported with extracorporeal membrane oxygenation.

Heng-Wen Chou1, Chih-Hsien Wang2, Lian-Yu Lin3, Nai-Hsin Chi2, Nai-Kuan Chou2, Hsi-Yu Yu4, Yih-Sharng Chen5.   

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an effective support method for acute fulminant myocarditis (AFM) with cardiogenic shock. However, deciding whether to bridge to a left ventricular assist device (LVAD) or to maintain ECMO support until heart recovery is still controversial.
MATERIAL AND METHODS: This was a retrospective observational study from a single center. Eighty-eight adults with AFM and ECMO support between 2006 and 2018 were included. The primary endpoint was heart recovery without heart transplantation or long-term LVAD support.
RESULTS: The heart recovery group contained 43 patients, of whom 41 were discharged after being weaned off ECMO and the other two after LVAD. Five patients with heart transplants and one with long-term LVAD support were discharged, accounting for an overall survival of 55.7%. Multivariate logistic regression revealed that peak CK-MB level, severe intraventricular conduction disturbance (asystole) and malignant arrhythmia (VT or VF) were prognostic factors for nonrecovery (P = .027 and 0.017, respectively), while early intravenous immunoglobulin (IVIG) use before ECMO was highly likely to have a protective effect with a trend toward statistical significance (P = .079). A risk score was developed: 4 points for VT/VF/asystole, 1 point for every 100 μg/L increase in the peak CK-MB level, up to a maximum of 5 points, and -3 points for early IVIG use. The area under the receiver operating characteristic (ROC) curve (AUC) was 0.818.
CONCLUSION: High CK-MB levels and VT/VF/asystole in patients with AFM are associated with poor heart recovery. Early IVIG use shows a potentially protective effect.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Acute myocarditis; Extracorporeal membrane oxygenation; Fulminant myocarditis; Intravenous immunoglobulin

Mesh:

Substances:

Year:  2020        PMID: 32220770     DOI: 10.1016/j.jcrc.2020.03.007

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  3 in total

1.  The Early Dynamic Change in Cardiac Enzymes and Renal Function Is Associated with Mortality in Patients with Fulminant Myocarditis on Extracorporeal Membrane Oxygenation: Analysis of a Single Center's Experience.

Authors:  Ching-Lin Ho; Teressa Reanne Ju; Chi Chan Lee; Hsin-Ti Lin; Alexander-Lee Wang; Robert Jeenchen Chen; You-Cian Lin
Journal:  Healthcare (Basel)       Date:  2022-06-08

Review 2.  Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.

Authors:  Maryam Amini Pouya; Seyyedeh Maryam Afshani; Armin Salek Maghsoudi; Shokoufeh Hassani; Kayvan Mirnia
Journal:  Daru       Date:  2020-07-30       Impact factor: 3.117

3.  Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.

Authors:  Enrico Ammirati; Maria Frigerio; Leslie T Cooper; Paolo G Camici; Eric D Adler; Cristina Basso; David H Birnie; Michela Brambatti; Matthias G Friedrich; Karin Klingel; Jukka Lehtonen; Javid J Moslehi; Patrizia Pedrotti; Ornella E Rimoldi; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Circ Heart Fail       Date:  2020-11-12       Impact factor: 8.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.